| Not Yet Recruiting | An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye NCT07438405 | Amgen | Phase 2 |
| Not Yet Recruiting | An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) NCT07462130 | Nanjing Chia-tai Tianqing Pharmaceutical | Phase 1 / Phase 2 |
| Not Yet Recruiting | Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Diseas NCT07308964 | Sheba Medical Center | Phase 4 |
| Not Yet Recruiting | A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease NCT07265258 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 4 |
| Recruiting | Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. NCT07423013 | Peking University Third Hospital | N/A |
| Recruiting | A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease NCT07113262 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Completed | Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients NCT07085117 | Amgen | — |
| Active Not Recruiting | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) NCT07155668 | Viridian Therapeutics, Inc. | Phase 3 |
| Terminated | Evaluation of K9 in Subjects With Thyroid Eye Disease (TED) NCT06467435 | Peter Timoney | Phase 1 |
| Active Not Recruiting | A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease NCT06557850 | H. Lundbeck A/S | Phase 1 |
| Completed | A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye Disease NCT06525506 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 |
| Active Not Recruiting | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) NCT06625411 | Viridian Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED) NCT06625398 | Viridian Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult NCT06248619 | Amgen | Phase 3 |
| Recruiting | A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease NCT06401044 | Amgen | Phase 1 / Phase 2 |
| Completed | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease ( NCT06384547 | Viridian Therapeutics, Inc. | Phase 3 |
| Not Yet Recruiting | Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy NCT06413043 | All India Institute of Medical Sciences, Bhubaneswar | N/A |
| Terminated | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. NCT06307626 | argenx | Phase 3 |
| Terminated | A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease NCT06307613 | argenx | Phase 3 |
| Unknown | Evaluation of the Corneal Endothelial Cell Layer by Specular Microscopy in Patients With Thyroid Eye Disease NCT06235372 | Assiut University | — |
| Completed | A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease NCT06226545 | Lassen Therapeutics Inc. | Phase 2 |
| Recruiting | A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye D NCT06088979 | Tourmaline Bio, Inc. | Phase 2 |
| Completed | An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301 NCT06179875 | Viridian Therapeutics, Inc. | Phase 3 |
| Recruiting | Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease NCT06359795 | Peking University Third Hospital | N/A |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participan NCT06106828 | Hoffmann-La Roche | Phase 3 |
| Completed | An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye NCT06021054 | Viridian Therapeutics, Inc. | Phase 3 |
| Active Not Recruiting | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participan NCT05987423 | Hoffmann-La Roche | Phase 3 |
| Recruiting | Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TE NCT06112340 | Sling Therapeutics, Inc. | Phase 2 / Phase 3 |
| Completed | Study of ZB001 in Chinese Patients With Thyroid Eye Disease NCT05776121 | Zenas BioPharma (USA), LLC | Phase 1 |
| Recruiting | Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting NCT05012033 | Imperial College London | — |
| Completed | Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED) NCT05683496 | ACELYRIN Inc. | Phase 1 / Phase 2 |
| Completed | A Study of IBI311 in Subjects With Active Thyroid Eye Disease NCT05795621 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 / Phase 3 |
| Completed | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease NCT05524571 | Immunovant Sciences GmbH | Phase 3 |
| Completed | Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease NCT05517421 | Immunovant Sciences GmbH | Phase 3 |
| Active Not Recruiting | Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease NCT05517447 | Immunovant Sciences GmbH | Phase 3 |
| Withdrawn | The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease NCT02422368 | Iran University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | A Study of TEPEZZA® Treatment in Participants With Thyroid Eye Disease NCT06389578 | Amgen | Phase 1 |
| Active Not Recruiting | A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) NCT05276063 | Sling Therapeutics, Inc. | Phase 2 / Phase 3 |
| Completed | A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subj NCT05331300 | Lassen Therapeutics 1 PTY LTD | Phase 1 / Phase 2 |
| Completed | Development of an AI Solution to Evaluate Clinical Activity of TAO Using Periocular Images Taken by Smartphone NCT05731154 | Seoul National University Bundang Hospital | — |
| Completed | A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With NCT05176639 | Viridian Therapeutics, Inc. | Phase 3 |
| Completed | Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease NCT04976816 | Assiut University | Phase 2 / Phase 3 |
| Terminated | A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) NCT04737330 | Novartis Pharmaceuticals | Phase 3 |
| Completed | TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study NCT05002998 | Amgen | Phase 4 |
| Completed | A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease NCT04583735 | Amgen | Phase 4 |
| Recruiting | Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease) NCT06367517 | Medical University of Warsaw | — |
| Recruiting | The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction NCT06275373 | Walter Reed National Military Medical Center | — |
| Unknown | AS-OCT of the Cornea in Thyroid Diseases NCT05241626 | Minia University | — |
| Unknown | Customized Multiple Orbital Wall Decompression for Sight-threatening Graves's Ophthalmopathy NCT05627401 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Completed | Anti-VEGF Therapy for Acute Thyroid Eye Disease NCT04311606 | Massachusetts Eye and Ear Infirmary | Phase 2 |
| Unknown | Tamsulosin for Thyroid Lid Retraction NCT04359979 | Sheba Medical Center | N/A |
| Withdrawn | The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED) NCT02393183 | Iran University of Medical Sciences | Phase 2 / Phase 3 |
| Completed | Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Ext NCT03461211 | Amgen | Phase 3 |
| Completed | Corneal Tomographic Parameters in TGD NCT04433936 | Ameera Gamal Abdelhameed | — |
| Completed | Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Ra NCT03298867 | Amgen | Phase 3 |
| Terminated | Celecoxib for Thyroid Eye Disease NCT02845336 | Johns Hopkins University | Phase 2 |
| Terminated | B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease NCT02316691 | University of Pittsburgh | — |
| Unknown | The Therapeutic Effect of Dysthyroid Optic Neuropathy NCT04096612 | Sun Yat-sen University | N/A |
| Withdrawn | The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. NCT01927406 | Stanford University | Phase 4 |
| Terminated | Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease NCT01738243 | University of California, Los Angeles | Phase 4 |
| Completed | Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease NCT01798966 | Sensimed AG | N/A |
| Completed | Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) NCT01297699 | Hospital Clinico Universitario de Santiago | Phase 3 |
| Completed | Disappearance of Graves' Orbitopathy NCT03103607 | University of Pisa | — |
| Approved For Marketing | Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease NCT04040894 | Amgen | — |